Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort-Reference-Cited by-同舟云学术

Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort

Published:2024-02-01 Issue:2 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Decker Slade¹,Xiao Shaoming¹,Dillen Carly²,Schumacher Christina M¹,Milstone Aaron M¹³,Frieman Matthew²,Debes Amanda K³^ORCID

Affiliation:

1. Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

2. Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland , USA

3. Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland , USA

Abstract

Abstract Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/article-pdf/11/2/ofad625/56663964/ofad625.pdf

Reference10 articles.

1. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19);Boucau;Clin Infect Dis,2022

2. Rebound of SARS-CoV-2 infection after nirmatrelvir–ritonavir treatment;Charness;N Engl J Med,2022

3. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology;Newton;Semin Immunopathol,2016